Nintedanib Sandoz (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR—thereby inhibiting the signaling that leads to fibroblast proliferation, new blood‑vessel formation and extracellular‑matrix deposition. This multi‑target inhibition reduces fibrotic tissue remodeling and can also limit tumor angiogenesis when used with other anticancer agents.

The specific dose and dosing schedule of Nintedanib Sandoz are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Healthcare professionals follow the approved labeling and adjust the regimen as needed for safety and efficacy.

The safety of Nintedanib in pregnancy and lactation has not been established. It is classified as contraindicated unless the potential benefit justifies the potential risk to the fetus. Women of child‑bearing potential should use effective contraception, and breastfeeding mothers should discuss alternatives with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nintedanib differs from other antifibrotics such as pirfenidone by targeting a broader range of tyrosine‑kinase receptors, which may provide additional benefit in certain fibrotic pathways. Clinical trials have shown comparable efficacy in slowing lung‑function decline, but the side‑effect profile and drug‑interaction potential vary, requiring individualized selection by the treating physician.

Nintedanib Sandoz capsules should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

The medication is supplied as oral capsules and is taken by mouth, usually with food to lessen gastrointestinal discomfort. Patients should swallow the capsule whole with water and follow the dosing instructions provided by their healthcare professional.

Serious risks include significant liver enzyme elevations indicating possible hepatic injury, bleeding complications especially when combined with anticoagulants, and rare cardiovascular events such as heart failure or hypertension exacerbation. Patients should be monitored regularly for these adverse outcomes.

Nintedanib is contraindicated in patients with severe hepatic impairment, those with active bleeding disorders, and individuals taking strong CYP3A4 inhibitors that cannot be discontinued. It should also be avoided in patients who are pregnant unless the benefit outweighs the risk, and in anyone with known hypersensitivity to the drug or its excipients.